Safety and Efficiency of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT: a Prospective, Single-arm, Single-center, Phase II Study. is a PHASE2 clinical asset sponsored by Institute of Hematology & Blood Diseases Hospital, China in Multiple Myeloma. SEO and diligence focus: anti-BCMA CAR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.